Available carbapenems: Properties and differences;Los carbapenems disponibles: Propiedades y diferencias

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 28, Issue SUPPL. 2, 2010, Pages 53-64

  Fresnadillo Martínez, María José ^a   García García, María Inmaculada ^b   García Sánchez, Enrique ^a   García Sánchez, José Elías ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Carbapenems ; Doripenem; Clinical use; Resistance

Indexed keywords

DORIPENEM; ERTAPENEM;

ACINETOBACTER; ANTIMICROBIAL ACTIVITY; ARTICLE; COMMUNICABLE DISEASE; DRUG ACTIVITY; DRUG SAFETY; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; MONOTHERAPY; PSEUDOMONAS AERUGINOSA;

ABDOMEN; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BIOLOGICAL AVAILABILITY; CARBAPENEMS; CELL WALL; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TISSUE DISTRIBUTION;

EID: 79551538672     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(10)70031-8     Document Type: Article

References (80)

1. J.S. Kahan, F.M. Kahan, R. Goelgelman, S.A. Currie, M. Jackson, and E.O. Stapley Thiena-mycin, a new β-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties J Antibiot 32 1979 1 12
2. a ed 2006 Prous Science Barcelona 173 187
3. R.C. Moellering Jr., G.M. Eliopoulos, and D.E. Sentochnik The carbapenems: new broad spectrum β-lactam antibiotics J Antimicrob Chemother 24 Suppl A 1989 1 7
4. M.L. Hammond Ertapenem: a group 1 carbapenem with distinct antibacterial and pharmacological properties J Antimicrob Chemother 53 Suppl 2 2004 7 9
5. J. Quale, S. Bratu, J. Gupta, and D. Landman Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates Antimicrob Agents Chemother 50 2006 1633 1641
6. J.R. Edwards, and P.J. Turner Laboratory data which differentiate meropenem and imipenem Scand J Infect Dis 96 Suppl 1995 5 10
7. Y. Iso, T. Irie, Y. Nishino, K. Motokawa, and Y. Nishitani A novel 1 beta-methylcarbape-nem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1 beta-methylcarbapenems J Antibiot (Tokyo) 49 1996 199 209
8. D.P. Nicolau Carbapenems: a potent class of antibiotics Expert Opin Pharmacother 9 2008 23 37
9. G. Poulakou, and H. Giamarellou Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens Expert Opin Investig Drugs 17 2008 749 771
10. S.J. Keam Doripenem: a review of its use in the treatment of bacterial infections Drugs 68 2008 2021 2057
11. W.C. Hellinger, and N.S. Brewer Carbapenems and monobactams: imipenem, meropenem, and aztreonam Mayo Clin Proc 74 1999 420 434
12. D.N. Fish, and T.J. Singletary Meropenem, a new carbapenem antibiotic Pharmacotherapy 17 1997 644 669
13. R.N. Jones, H.K. Huynh, D.J. Biedenbach, T.R. Fritsche, and H.S. Sader Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations J Antimicrob Chemother 54 2004 144 154
14. S. Lemaire, F. Van Bambeke, M.P. Mingeot-Leclercq, and P.M. Tulkens Activity of three {beta}-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus J Antimicrob Chemother 55 2005 897 904
15. N.D. Greer Doripenem (Doribax): the newest addition to the carbapenems Proc (Bayl Univ Med Cent) 21 2008 337 341
16. T.A. Davies, W. Shang, K. Bush, and R.K. Flamm Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa Antimicrob Agents Chemother 52 2008 1510 1512
17. J.J. Jackson, and H. Kropp β-lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime J Infect Dis 165 1992 1033 1041
18. S.J. Matthews, and J.W. Lancaster Doripenem monohydrate, a broad-spectrum carbapenem antibiotic Clin Ther 31 2009 42 63
19. T.A. Davies, W. Shang, K. Bush, and R.K. Flamm Activity of doripenem and comparator beta-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x J Antimicrob Chemother 61 2008 751 753
20. M. Souli, I. Galani, and H. Giamarellou Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe Euro Surveill 13 2008 19045
21. G.M. Rossolini, and E. Mantengoli Antimicrobial resistance in Europe and its potential impact on empirical therapy Clin Microbiol Infect 14 Suppl 6 2008 2 8
22. C. Neuwirth, E. Siébor, J.M. Duez, A. Péchinot, and A. Kazmierczak Imipenem resistance in clinical isolates of Proteus mirabilis associated with alterations in penicillin-binding proteins J Antimicrob Chemother 36 1995 335 342
23. D. Livingstone, M.J. Gill, and R. Wise Mechanisms of resistance to the carbapenems J Antimicrob Chemother 35 1995 1 5
24. R.N. Jones, H.K. Huynh, and D.J. Biedenbach Activities of doripenem (S-4661) against drug-resistant clinical pathogens Antimicrob Agents Chemother 48 2004 3136 3140
25. C.M. Pillar, M.K. Torres, N.P. Brown, D. Shah, and D.F. Sahm In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States Antimicrob Agents Chemother 52 2008 4388 4399
26. R.E. Mendes, P.R. Rhomberg, J.M. Bell, J.D. Turnidge, and H.S. Sader Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents Diagn Microbiol Infect Dis 63 2009 415 425
27. R.N. Jones, H.S. Sader, and T.R. Fritsche Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lacta-mase resistance mechanisms Diagn Microbiol Infect Dis 52 2005 71 74
28. A.M. Queenan, and K. Bush Carbapenemases: the versatile beta-lactamases Clin Microbiol Rev 20 2007 440 458
29. F. Walsh Doripenem: a new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities Ther Clin Risk Manag 3 2007 789 794
30. K. Bandoh, K. Watanabe, Y. Muto, Y. Tanaka, N. Kato, and K. Ueno Conjugal transfer of imipenem resistance in Bacteroides fragilis J Antibiot (Tokyo) 45 1992 542 547
31. J. Joseph, and K.A. Rodvold The role of carbapenems in the treatment of severe nosoco-mial respiratory tract infections Expert Opin Pharmacother 9 2008 561 575
32. R. Tibbetts, J.G. Frye, J. Marschall, D. Warren, and W. Dunne Detection of KPC-2 in a clinical isolate of Proteus mirabilis and first reported description of carbapenemase resistance caused by a KPC beta-lactamase in P mirabilis J Clin Microbiol 46 2008 3080 3083
33. D.J. Wolter, P.M. Kurpiel, N. Woodford, M.F. Palepou, R.V. Goering, and N.D. Hanson Pheno-typic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4 Antimicrob Agents Chemother 53 2009 557 562
34. J. Walther-Rasmussen, and N. Høiby Class A carbapenemases J Antimicrob Chemother 60 2007 470 482
35. J.E. Hugonnet, L.W. Tremblay, H.I. Boshoff, C.E.3rd Barry, and J.S. Blanchard Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis Science 323 2009 1215 1218
36. T.R. Fritsche, H.S. Sader, M.G. Stillwell, and R.N. Jones Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007) Diagn Microbiol Infect Dis 63 2009 440 446
37. L. Poirel, and P. Nordmann Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology Clin Microbiol Infect 12 2006 826 836
38. S. Mushtaq, Y. Ge, and D.M. Livermore Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp with characterized beta-lactamases Antimicrob Agents Chemother 48 2004 1313 1319
39. R. Nordmann, G. Cuzon, and T. Naas The real threat of Klebsiella pneumoniae carbapene-mase-producing bacteria Lancet Infect Dis 9 2009 228 236
40. L. Poirel, J.D. Pitout, and P. Nordmann Carbapenemases: molecular diversity and clinical consequences Future Microbiol 2 2007 501 512
41. A. Carrër, L. Poirel, H. Eraksoy, A.A. Cagatay, S. Badur, and P. Nordmann Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey Antimicrob Agents Chemother 52 2008 2950 2954
42. Y. Carmeli, N. Troillet, G.M. Eliopoulos, and M.H. Samore Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antip-seudomonal agents Antimicrob Agents Chemother 43 1999 1379 1382
43. D.M. Livermore Of Pseudomonas, porins, pumps and carbapenems J Antimicrob Chemother 47 2001 247 250
44. R.E.W. Hancock, and D.P. Speert Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment Drug Resist Updates 3 2000 247 255
45. S. Mushtaq, Y. Ge, and D.M. Livermore Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential Antimicrob Agents Chemother 48 2004 3086 3092
46. T.R. Walsh Clinically significant carbapenemases: an update Curr Opin Infect Dis 21 2008 367 371
47. J.N. Kattan, M.V. Villegas, and J.P. Quinn New developments in carbapenems Clin Microbiol Infect 14 2008 1102 1111
48. S.D. Brown, and M.M. Traczewski Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control J Antimicrob Chemother 55 2005 944 949
49. D.R. Snydman, N.V. Jacobus, and L.A. McDermott In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group Antimicrob Agents Chemother 52 2008 4492 4496
50. T.R. Fritsche, M.G. Stilwell, and R.N. Jones Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003) Clin Microbiol Infect 11 2005 974 984
51. M. Castanheira, R.N. Jones, and D.M. Livermore Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp Diagn Microbiol Infect Dis 63 2009 426 433
52. E.J. Goldstein, and D.M. Citron Activity of a novel carbapenem, doripenem, against anaerobic pathogens Diagn Microbiol Infect Dis 63 2009 447 454
53. R.N. Jones, J.M. Bell, H.S. Sader, J.D. Turnidge, and M.G. Stilwell In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens Diagn Microbiol Infect Dis 63 2009 434 439
54. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement. M100-S18. 2008.
55. D.M. Livermore, K.J. Oakton, M.W. Carter, and M. Warner Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases Antimicrob Agents Chemother 45 2001 2831 2837
56. M.M. Traczewski, and S.D. Brown In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients Antimicrob Agents Chemother 50 2006 819 821
57. Y. Chen, E. Garber, Q. Zhao, Y. Ge, M.A. Wikler, and K. Kaniga In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis Antimicrob Agents Chemother 49 2005 2510 2511
58. S.F. Yeo, and D.M. Livermore Comparative in vitro activity of biapenem and other carbapenems against Haemophilus influenzae isolates with known resistance mechanisms to ampicillin J Antimicrob Chemother 33 1994 861 865
59. D.M. Livermore Doripenem: antimicrobial profile and clinical potential Diagn Microbiol Infect Dis 63 2009 455 458
60. Y. Ge, M.A. Wikler, D.F. Sahm, R.S. Blosser-Middleton, and J.A. Karlowsky In vitro antimicrobial activity of doripenem, a new carbapenem Antimimicrob Agents Chemother 48 2004 1384 1396
61. S. Martí, J. Sánchez-Céspedes, V. Alba, and J. Vila In vitro activity of doripenem against Acinetobacter baumannii clinical isolates Int J Antimicrob Agents 33 2009 181 182
62. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement (June 2010 Update). M100-S20. 2010.
63. EUCAST. Disponible en: http://www.srga.org/eucastwt/MICTAB/ MICcarbapenems.html.
64. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Nineteenth Informational Supplement. M100-S19. 2009.
65. V. Fernández Gallego, M.J. Muñoz Juárez, J. Honorato Pérez, and I. Gil Aldea Farmacoci-nética y farmacodinamia de ertapenem Enferm Infecc Microbiol Clin 3 Supl 2004 22 26
66. P.A. Psathas, A. Kuzmission, K. Ikeda, and S. Yasuo Stability of doripenem in vitro in representative infusion solutions and infusion bags Clin Ther 30 2008 2075 2087
67. L.R. Moczygemba, C.R. Frei, and D.S. Burgess Pharmacodynamic modeling of carbape-nems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases Clin Ther 26 2004 1800 1807
68. D.E. Nix, A.K. Majumdar, and M.J. DiNubile Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians J Antimicrob Chemother 53 Suppl 2 2004 23 28
69. K. Ikawa, N. Morikawa, S. Uehara, K. Monden, Y. Yamada, and N. Honda Pharmaco-kinetic-pharmacodynamic target attainment analysis of doripenem in infected patients Int J Antimicrob Agents 33 2009 276 279
70. J.F. Mohr Update on the efficacy and tolerability of Meropenem in the treatment of serious bacterial infections Clin Infect Dis 47 Suppl 1 2008 S41 51
71. C.C. John, G. Aouad, B. Berman, and J.R. Schreiber Successful meropenem treatment of multiply resistant pneumococcal meningitis Pediatr Infect Dis J 16 1997 1009 1011
72. Agencia Europea del Medicamento (EMEA). Diponible en: http://www.emea.euro-pa.eu/
73. C. Lucasti, A. Jasovich, O. Umeh, J. Jiang, K. Kaniga, and I. Friedland Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdomi-nal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study Clin Ther 30 2008 868 883
74. O. Malafaia, O. Umeh, and J. Jiang Doripenem versus meropenem for the treatment of complicated intra-abdominal infections 2006 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) San Francisco CA. L-1564b September 27-30 Poster
75. J.S. Solomkin, O. Umeh, J. Jiang, K. Kaniga, and I. Friedland Doripenem vs meropenem with an option for oral step-down therapy in the treatment of complicated intra-abdominal infections 2007 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Chicago IL L-487 September 17-20 Poster
76. A. Réa-Neto, M. Niederman, S.M. Lobo, E. Schroeder, M. Lee, and K. Kaniga Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study Curr Med Res Opin 24 2008 2113 2126
77. J. Chastre, R. Wunderink, R. Prokocimer, M. Lee, K. Kaniga, and I. Friedland Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-asso-cia-ted pneumonia: a multicenter, randomized study Crit Care Med 36 2008 1089 1096
78. K. Naber, R. Redman, R. Kotey, L. Llorens, and K. Kaniga Intravenous therapy with doripenem versus levofloxacin with an option for oral step-down therapy in the treatment of complicated urinary tract infections and pyelonephritis 2007 17th European Congress of Clinical Microbiology and Infectious Diseases Munich Germany P833 March 31-April 3 Poster
79. R.C. Owens Jr. An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in? Crit Care 12 Suppl 4 2008 S3
80. H.K. Huynh, D.J. Biedenbach, and R.N. Jones Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an amino-glycoside Diagn Microbiol Infect Dis 55 2006 241 243